SC134-deruxtecan,一种用于小细胞肺癌治疗的针对性ADC
Bryony Heath1, Bubacarr G Kaira1, Dhruma Thakker1
1Scancell Limited, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
Journal of translational medicine
|August 20, 2025
概括
一种新型抗体药物结合物SC134-德鲁克斯坦有效向小细胞肺癌 (SCLC) 细胞的Fucosyl-GM1. 这种向治疗显示出对SCLC异种移植的强大临床前疗效,耐受性良好.
科学领域:
- 癌症学
- 免疫疗法
- 葡萄糖生物学
背景情况:
- 小细胞肺癌 (SCLC) 具有重大治疗挑战,长期存活率有限.
- 富科西尔-GM1 (FucGM1) 是一种瘤特异性甘油脂,在SCLC中高度表达,使其成为一个有吸引力的治疗点.
- 现有疗法只能提供适度的生存效益,强调需要新的治疗策略.
研究的目的:
- 开发和表征SC134-deruxtecan,一种针对Fucosyl-GM1 (FucGM1) 的抗体药物联合体 (ADC),用于治疗SCLC.
- 评估SC134- 德鲁克斯坦对SCLC的临床前活性,特异性和疗效.
主要方法:
- 使用ELISA,SPR,流细胞计和免疫组织化学评估了SC134的结合特异性和亲和力.
- 为了了解SC134-FucGM1的相互作用,使用了模型.
- 在异种移植模型中评估了内部化,溶酶体局部化,细胞毒性,旁观者杀死,ADCC和体内疗效.
主要成果:
- SC134对FucGM1表现出特定的纳米分子亲和力,而没有对GM1的交叉反应.
- 在实验室中,SC134- deruxtecan表现出强烈的SCLC细胞杀死,包括旁观者效应和ADCC增强.
- 在体内研究显示,使用SC134-德鲁克斯坦3mg/ kg具有强烈的SCLC异种移植瘤杀死效果,耐受性良好.
结论:
- 瘤特异性的FucGM1表达和强大的SCLC杀死活性可支持其作为SCLC的ADC疗法的潜力.
- 由于其特定的向和强大的临床前疗效,SC134- deruxtecan对向性SCLC治疗具有前景.
更多相关视频
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
10:33Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
371
相关概念视频
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81